The Role of IL-33 Staining as a Biomarker and Immunotherapeutic Target


About this study

We are evaluating interleukin-33 and innate lymphoid cells in non-small cell lung cancer to further explain underlying mechanisms and assess their potential as prognostic biomarkers and targets in treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

Participants over the age of 18 who are scheduled to have non-small cell lung tumors greater than 2.5 cm surgically resected.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Tobias Peikert, M.D.

Contact us for the latest status

Contact information:

Virginia Van Keulen


More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer